Citigroup maintains Attovia Therapeutics at Buy, raises price target to $34 from $30
Citigroup kept its Buy rating on Attovia Therapeutics and increased its price target to $34 from $30, suggesting a 113% upside from the Nov 9 close of $15.96, according to the bank.


